Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis

Abstract The course of multiple sclerosis (MS) can be monitored by measuring changes in brain volume, but consensus is still lacking on the best strategy to be adoped. We compared the reproducibility and sensitivity of volume measurements from different brain portions for detecting changes on magnetic resonance imaging (MRI) in patients with MS. T1-weighted MRI of the brain was performed in 50 patients with relapsing-remitting MS at study entry and after an average follow-up of 18.4 months. Using a semiautomated technique for brain parenchyma segmentation, the volumes of the following brain portions were measured: (a) the whole brain (whole brain volume, WBV), (b) the seven slices rostral to the velum interpositum (seven-slice volume, SSV), (c) the central slice of the image set (central-slice volume, CSV) and (d) the infratentorial regions (infratentorial-brain volume, IBV). All these measurements were carried out by a single observer and were repeated twice on ten randomly selected scans to test the intra-observer reproducibility using the four strategies. At follow-up there was a significant decrease in all the measures of brain volume (P ranged from 0.002 to < 0.001). The univariate correlations between changes in WBV, SSV, CSV and IBV were all statistically significant, with the exception of that between changes in CSV and IBV; r values ranged from 0.34 (for the WBV/IBV correlation) to 0.80 (for the WBV/SSV correlation). The mean intra-observer coefficient of variations were 1.9% for WBV, 1.5% for SSV, 2.9% for CSV and 2.2% for IBV measurements. The measurement of volume on a portion of brain selectively including the regions in which MS pathology is more diffuse is as reliable and sensitive to disease-related changes as that on the whole brain, with significant time saving for processing.

[1]  J K Udupa,et al.  Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS , 2000, Neurology.

[2]  L D Blumhardt,et al.  Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[3]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[4]  I. Allen,et al.  A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis , 1979, Journal of the Neurological Sciences.

[5]  Caterina Mainero,et al.  Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability , 2000, Journal of the Neurological Sciences.

[6]  M Rovaris,et al.  Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. , 1999, Current opinion in neurology.

[7]  Massimo Filippi,et al.  Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis , 1995, Journal of the Neurological Sciences.

[8]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[9]  W. Jagust,et al.  Brain atrophy as a surrogate marker in MS , 2000, Neurology.

[10]  P M Matthews,et al.  Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. , 1998, Brain : a journal of neurology.

[11]  J M Bland,et al.  Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .

[12]  M. Rovaris,et al.  Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study , 1999, Journal of the Neurological Sciences.

[13]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[14]  J K Udupa,et al.  Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.

[15]  Massimo Filippi,et al.  Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis , 1998, Journal of the Neurological Sciences.

[16]  T. Hammeke,et al.  Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. , 1985, Archives of neurology.

[17]  L D Blumhardt,et al.  Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. , 1999, Brain : a journal of neurology.

[18]  L A Loizou,et al.  Cranial computed tomography in the diagnosis of multiple sclerosis. , 1982, Journal of neurology, neurosurgery, and psychiatry.

[19]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[20]  F. Barkhof,et al.  Primary and transitional progressive MS , 1999, Neurology.

[21]  P. Dastidar,et al.  Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis , 1999, Journal of the Neurological Sciences.

[22]  M Filippi,et al.  The effect of imprecise repositioning on lesion volume measurements in patients with multiple sclerosis , 1997, Neurology.

[23]  A. Thompson,et al.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.

[24]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[25]  C. Raine Comparative neuropathology and immunopathology of multiple sclerosis and HTLV-1 myelopathy , 1992, Journal of Neuroimmunology.

[26]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[27]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[28]  R. Herndon,et al.  A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.

[29]  Ludwin Sk,et al.  The neuropathology of multiple sclerosis. , 2000 .

[30]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[31]  H. Adams,et al.  Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.